Australia’s National Research Infrastructure (NRI) swiftly redeployed to support national and international COVID-19 research. Some examples are listed below.
Australian Centre for Disease Preparedness (ACDP), Bioplatforms Australia (BPA), Microscopy Australia and Therapautic Innovation Australia (TIA) were involved in the University of Queensland vaccine program.
Australian Plant Phenomics Facility (APPF) is supporting research into plant-based vaccines.
Astronomy Australia Ltd (AAL), BPA and the National Imaging Facility (NIF) are supporting diagnosis of COVID-19.
BPA was also involved in a wide variety of support for COVID-19 researchers, particularly when in creating molecules and sequencing DNA.
ACDP, Phenomics Australia, Microscopy Australia (MA) and the NIF are heavily involved in supporting COVID-19 research.
ACDP is also testing multiple vaccine candidates, including the Oxford vaccine now being rolled out in the UK.
EMBL Australia researchers led a vaccine trial, developed an AI tool to detect viral co-infections and researched disease prevention across species.
The Australian National Fabrication Facility (ANFF), TIA, National Computational Infrastructure (NCI) and Pawsey Supercomputing Centre reprioritised their services to offer their infrastructure support to COVID-19 research projects, and are each supporting a wide variety of COVID-19 projects.
ANFF is manufacturing and validating protective equipment (PPE) for Australian healthcare workers, and MA is also involved in manufacturing PPE and diagnostic kits.
NIF is also involved in lung MRI to improve treatments, and developing a low-cost, easy-to-use ventilators and 3D printed adjuncts for respirators.
The NCRIS-supported National Deuteration Facility (NDF) and Australian Centre for Neutron Scattering (ACNS) at ANSTO are assessing reusability of N95 masks and performing large scale production of an important COVID-19-related molecule.
Genomic analyses of COVID-19 have been published on a platform supported by BPA and the Australian Research Data Commons (ARDC).
TIA developed a treatment to reduce or prevent lung damage associated with COVID-19.
COVID-19 related data is being linked by the Population Health Research Network (PHRN) to support analysis by researchers and media, and by the Australian Urban Research Infrastructure Network (AURIN) to predict and track impacts on the healthcare system and property market.
PHRN is also specifically supporting many state-based health projects.
The NCRIS projects are also helping fill gaps in research data caused by travel restrictions or other countries not faring as well during the pandemic, with AAL, Terrestrial Ecosystem Research Network and Atlas of Living Australia all seeing spikes in their content being accessed.
This agile and rapid response capability keeps Australia at the forefront of emerging global responses. This is enabled both through coordinated priorities, investments, and collaborative activities – both within and between individual NCRIS capability projects.